Mayur AGRAWAL, Abhijit RATHI
Journal of Clinical Trials and Experimental Investigations - 2026;5(2):0-0
Objective: Type 2 diabetes mellitus (T2DM) is often complicated by the challenge of achieving and sustaining meaningful weight reduction, along with gastrointestinal discomfort, particularly in patients receiving Glucagon-like Peptide-1 (GLP-1) agonist therapy. These complications can impair adherence and reduce quality of life. Materials and methods: This single-arm, placebo-controlled, pilot study enrolled 30 adults with T2DM on GLP-1 agonist therapy. All participants received placebo supplementation during the first 30 days, followed by IP (SlimSEB(R)) supplementation for the subsequent 30 days. Assessments were conducted at the start of treatment (SOT) and end of treatment (EOT), focusing on health-related quality of life (HRQOL; SF36), anthropometric parameters, gastrointestinal symptom relief (GSRS) and safety monitoring. Results: All the 30 participants completed the study. IP led to marked improvements in quality of life and anthropometric parameters of the subjects. Daily supplementation for 30 days resulted in statistically significant reduction in bodily pain, and an improvement in social functioning, and vitality/energy post-intervention by 28.61%, 25% and 12.49%, and demonstrated better efficacy over placebo (p < 0.05). Positive changes were also observed in physical functioning with scores improving by 5% in the IP over 3.75% in the placebo group. IP significantly reduced the body weight, BMI waist circumference, and body fat by 1.60 kg (2.1%, p < 0.01), 0.36 kg/m2 (1.2%, p = 0.04), 1.11 cm (1.21%, p < 0.01) and 0.86% (2.59%, p < 0.01), over the placebo. GSRS scores showed significant reductions in abdominal pain (27.48%), indigestion (20.90%), and constipation (26.37%), highlighting the gastrointestinal benefits of supplementation. The data also showcased that IP was well tolerated at the studied dose, and no AEs and/or SAEs were reported during the clinical study. Conclusion: These preliminary findings highlight that daily intake of IP could provide multidimensional benefits in patients with T2DM on GLP-1 therapy, encompassing improved quality of life, weight regulation and enhanced gastrointestinal tolerability. Further, double-blinded, randomized, clinical trials with larger study populations, and prolonged duration are needed to warrant these findings and elucidate the underlying mechanisms.